Asserta Well being affords a novel healthcare cost utility that upends the present methodology within the US by permitting instant money funds. Its platform affords employers and sufferers extra accessibility, affordability, and ease in a market infamous for being none of these.
Asserta Well being is led by a robust and succesful staff with deep expertise in healthcare and healthcare funds. As such, the staff has been in a position to develop the corporate to a decent dimension. Asserta Well being has processed greater than $40 million in funds and grew income 59.7% year-over-year, reaching $2.2 million in 2021. When it hires a brand new gross sales consultant with deep expertise in healthcare, the corporate could possibly develop even quicker. Lastly, the healthcare market is completely large, and any enchancment to the present approach of doing enterprise is an effective enchancment. Tendencies out there with the No Surprises Act may additionally speed up progress and increase the corporate’s prospects.
Sadly, Asserta Well being faces just a few predominant points: educating a populace, lengthy gross sales cycles, and medical health insurance carriers posing an existential risk. Whereas the training problem is much less of a risk and might be overcome with time, lengthy gross sales cycles and obstructionist insurance coverage carriers are notable threats. Medical insurance carriers are extraordinarily massive and highly effective. In the event that they deem Asserta Well being a risk, they will act as an enormous impediment to the corporate. As such, any large upside the corporate might have as an funding is balanced out by the draw back. For traders with excessive danger tolerance, this can be the startup for you. For others, Asserta Well being is probably not the very best funding alternative. Due to this fact, Asserta Well being seems to be a dangerous however high-end Impartial Deal.
For questions relating to the KingsCrowd analyst report or scores for this firm, please attain out to assist@kingscrowd.com.
Evaluation written by Francis Vu, July 29, 2022.
